诺华最新的临床试验挫折，为那些押注大型药企通过“小步快跑”式收购来充实研发管线的投资者，敲响了一记警钟。这一失败案例，生动地揭示了该策略背后潜藏的不确定性。
理论上，规模较小的交易能让巨头们以较低风险接触前景光明、利润可观的药物资产，避免豪赌式并购带来的巨大不确定性。一个典型的佐证是，当市场传言阿斯利康可能并购百时美施贵宝——倘若成真，将缔造一个估值约4000亿美元的制药帝国——阿斯利康股价随即遭遇剧烈抛售，投资者对巨型交易的风险厌恶情绪可见一斑。
然而，现实往往更为复杂。诺华在二月份完成的、对Avidity Biosciences价值120亿美元的收购案，生动地展示了即便是小型交易，也可能隐藏着同样沉重的代价。交易完成后，诺华股价在欧洲市场一度重挫10%。导火索是公司披露，该项收购中最先进的候选药物在针对1型强直性肌营养不良（一种遗传性神经肌肉疾病）的后期临床试验中，未能达到主要疗效终点。
这一挫折并非孤立事件。回溯至2024年，诺华已因对生物技术公司MorphoSys的29亿美元收购，计提了高达8亿美元的资产减值。接踵而至的研发失败与财务损失，无疑为整个制药行业的并购热潮，投下了一道耐人寻味的阴影。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.